# Theravex® for Burning Mouth Syndrome

> **NCT07564843** · NA · COMPLETED · sponsor: **Biointelligent Technology Systems SL** · enrollment: 116 (actual)

## Conditions studied

- Primary Burning Mouth Syndrome (BMS)

## Interventions

- **DEVICE:** THERAVEX® Total Oral Care Plus

## Key facts

- **NCT ID:** NCT07564843
- **Lead sponsor:** Biointelligent Technology Systems SL
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-06
- **Primary completion:** 2024-10-06
- **Final completion:** 2025-09-01
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07564843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07564843, "Theravex® for Burning Mouth Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07564843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*